Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very common in checkpoint inhibitors. We present 2 cases of bullous pemphigoid, as adverse reactions to pembrolizumab-treated MM.
Keywords: Adverse drug reaction; Autoimmune bullous diseases; Autoimmune diseases; Bullous pemphigoid; Bullous skin disease; Checkpoint inhibitors; Malignant melanoma; Pembrolizumab; Programmed cell death 1.